HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Bupivacaine (Bupivacaine Hydrochloride)

Subscribe to New Research on Bupivacaine

A widely used local anesthetic agent.

Also Known As:

Bupivacaine Hydrochloride; Marcaine; Sensorcaine; 1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide; Abbott Brand of Bupivacaine Hydrochloride; Astra Brand of Bupivacaine Hydrochloride; AstraZeneca Brand of Bupivacaine Hydrochloride; Aventis Brand of Bupivacaine Hydrochloride; Braun Brand of Bupivacaine Hydrochloride; Bupivacain Janapharm; Bupivacain-RPR; Bupivacaina Braun; Bupivacaine Anhydrous; Bupivacaine Carbonate; Bupivacaine Monohydrochloride, Monohydrate; Buvacaina; Carbostesin; Dolanaest; Inibsa Brand of Bupivacaine Hydrochloride; Jenapharm Brand of Bupivacaine Hydrochloride; Marcain; Pisa Brand of Bupivacaine Hydrochloride; Strathmann Brand of Bupivacaine Hydrochloride; Svedocain Sin Vasoconstr; Anhydrous, Bupivacaine; Braun, Bupivacaina; Bupivacain RPR; Carbonate, Bupivacaine; Hydrochloride, Bupivacaine; Janapharm, Bupivacain; 2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-

Networked: 3319 relevant articles (428 outcomes, 575 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Onel, Erol: 12 articles (02/2014 - 09/2011)
2.	Xu, Xuzhong: 7 articles (05/2015 - 12/2010)
3.	Viscusi, Eugene R: 6 articles (12/2015 - 02/2007)
4.	Strichartz, Gary R: 6 articles (10/2015 - 07/2005)
5.	Hadzic, Admir: 6 articles (09/2015 - 07/2004)
6.	Benhamou, Dan: 6 articles (07/2010 - 05/2004)
7.	Beloeil, Hélène: 6 articles (07/2010 - 04/2005)
8.	Ripper, Richard: 6 articles (09/2009 - 07/2006)
9.	Weinberg, Guy L: 6 articles (09/2009 - 07/2006)
10.	Hoka, Sumio: 6 articles (05/2009 - 01/2005)

Related Diseases

1.	Pain (Aches) 01/01/2015 - "We conducted this meta-analysis to summarize all published randomized controlled trials (RCTs), thus providing the most recent information on the safety and efficacy of single-administration IA bupivacaine for pain relief after arthroscopic knee surgery, and to determine whether a dose-response relationship exists. " 11/01/1994 - "Pain relief was superior in the bupivacaine series (P < 0.05) throughout the 24 hour study period and this was associated with significantly greater pulmonary ventilation compared with the PCA series. " 08/01/1992 - "From 4 h until the end of the study period, pain scores were significantly greater in the bupivacaine group than in the other two groups. " 04/01/1990 - "A double blind controlled randomised trial suggested that irrigation of third molar sockets with bupivacaine 0.75% produces significant reduction in pain scored on the first post-operative morning (p less than 0.01). " 01/01/1978 - "In general the results of the trial show that 0.125% bupivacaine had a significantly higher failure rate than either of the other two concentrations, but in those cases where 0.125% was effective and achieved total pain relief there was a significant reduction in the amount of the drug used."
2.	Postoperative Pain 01/01/2014 - "The advent of liposomal bupivacaine is proving to be a highly efficacious and safe method of postoperative pain management with favorable pharmacokinetics that reduces the risk of amide-related toxicity. " 04/01/2010 - "However, there was a significant reduction of postoperative pain in the bupivacaine group as well at rest as coughing. " 11/01/2005 - "A total of 154 patients had good postoperative pain relief for 72 h with continuous infusion of 0.05% bupivacaine. " 11/01/2003 - "Patient satisfaction with postoperative pain management (95 +/- 3 versus 77 +/- 13) and quality of recovery (96 +/- 7 versus 83 +/- 14) was significantly improved in the bupivacaine group (versus control). " 01/01/1999 - "bupivacaine, both produced equally good postoperative pain control and allowed a significant reduction of analgesic requirement after knee arthroscopy."
3.	Wounds and Injuries (Trauma) 01/01/2001 - "To assess the analgesic efficacy of patient-controlled bupivacaine wound instillation, 50 patients undergoing major intraabdominal surgery were enrolled into this prospective, placebo-controlled, double-blinded study. " 01/01/1999 - "Intraperitoneal bupivacaine is as effective as wound infiltration. " 08/01/1994 - "The analgesic efficacy of continuous intermuscular wound infusion with 0.25% bupivacaine was studied in 10 patients (four men, six women), with a mean age of 47.5 years (range 25-71) and a mean weight of 71.2 kg (range 44-99), after renal surgery in a single-blind randomized trial. " 04/01/1993 - "This study compares the efficacy of wound instillation with 0.25% bupivacaine (n = 20), caudal block with 0.25% bupivacaine (n = 35), and a control group (n = 15). " 05/01/1995 - "To compare the efficacy of preincision wound infiltration with bupivacaine to wound infiltration at the end of the operation. "
4.	Hypotension (Low Blood Pressure) 01/01/2000 - "The minidose combination caused dramatically less hypotension than 10 mg bupivacaine and nearly eliminated the need for vasopressor support of blood pressure." 01/01/2012 - "The intermediate dose of bupivacaine (5.5 mg) provided safe and effective anaesthesia for caesarean delivery with an additional advantage of lesser episodes of hypotension and partial motor blockade in CSEA." 02/05/2015 - "In addition, decreasing the dose of intrathecal bupivacaine could reduce the incidence of maternal hypotension." 04/01/2013 - "Hypotension occurred less frequently when spinal anaesthesia for caesarean using plain bupivacaine was induced with patients in the lateral compared with the sitting position. " 04/01/2012 - "The SMOFlipid emulsion is a option for reversing hypotension in cases of intoxication by bupivacaine."
5.	Nausea 08/01/2001 - "Nausea and antiemetic drug administration was significantly (P = 0.003) less in the Bupivacaine group. " 11/01/1995 - "The overall incidence of nausea was lower in the treatment group compared to the control group (Chi squared with Yates' correction p = 0.046) and a lower degree of sedation was seen in those receiving bupivacaine between 4 and 8 hours after commencing PCAS (Mann-Whitney U = 427, p = 0.028). " 01/01/1992 - "Nausea decreased after the initial dose with all treatments (p less than 0.01), whereas shivering increased in patients receiving bupivacaine (p less than 0.01). " 02/01/1999 - "In patients receiving bupivacaine compared with no injection, within 30 minutes postbanding there was a significant reduction in pain graded by the patient (P = 0.000002) and by the nurse (P = 0.000005) and a significant reduction in incidence of nausea (P = 0.01) and shaking (P = 0.008). " 05/01/2015 - "As a secondary outcome, at 24 hours, more patients in the bupivacaine group were headache free (24.7% difference; 95% CI 2.6% to 43.6%) and more were nausea free (16.9% difference; 95% CI 0.8% to 32.5%). "

Related Drugs and Biologics

1.	Morphine (MS Contin)
2.	Lidocaine (Xylocaine)
3.	Epinephrine (Adrenaline)
4.	Fentanyl (Sublimaze)
5.	ropivacaine (Naropin)
6.	Clonidine (ST 155)
7.	levobupivacaine (Chirocaine)
8.	Bupivacaine (Bupivacaine Hydrochloride)
9.	Liposomes (Liposome)
10.	Opioid Analgesics (Opioids)

Related Therapies and Procedures

1.	Analgesia
2.	Thoracotomy
3.	Cesarean Section (Caesarean Section)
4.	Laparoscopic Cholecystectomy
5.	Nerve Block (Nerve Blocks)